Trimel Pharmaceuticals Corporation announced that it has completed enrollment of its ongoing Tefina(TM) Phase II clinical trial. Tefina(TM) is being developed and clinically tested as a possible treatment for women suffering from Female Orgasmic Disorder. Participants enrolled in this trial are required to undergo a 28-day screening/baseline period as defined by the trial protocol.

During this period, participants are required to have a minimum of four sexual events. Women who experience an absence of orgasm during this baseline period and meet all other trial criteria are then permitted to continue in the study. These women are randomized into one of four treatment arms and then continue treatment for a period of 84 days.

The primary efficacy variable for the trial is the number of orgasms following administration of each of the dosage strengths of Tefina(TM) compared to placebo over the entire treatment period. The Tefina(TM) ambulatory clinical trial is being conducted primarily in the United States as well as in Australia and Canada. Trimel anticipates having top-line data available from this trial in the second quarter of 2014.